Axsome Therapeutics (AXSM) to Release Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is set to announce its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($1.30) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, May 6th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.11. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. The firm had revenue of $75.00 million for the quarter, compared to the consensus estimate of $69.91 million. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $84.42 on Friday. The business’s 50-day moving average price is $79.44 and its two-hundred day moving average price is $79.42. The company has a debt-to-equity ratio of 1.25, a current ratio of 3.20 and a quick ratio of 3.09. Axsome Therapeutics has a one year low of $55.02 and a one year high of $98.40. The company has a market capitalization of $4.01 billion, a P/E ratio of -13.23 and a beta of 1.26.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AXSM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price target on shares of Axsome Therapeutics in a research report on Friday, July 26th. Needham & Company LLC assumed coverage on Axsome Therapeutics in a research note on Monday, July 22nd. They set a “buy” rating and a $130.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $190.00 price target on shares of Axsome Therapeutics in a research note on Thursday, June 6th. Royal Bank of Canada restated an “outperform” rating and set a $131.00 price target on shares of Axsome Therapeutics in a research note on Monday, July 22nd. Finally, Robert W. Baird upped their price objective on Axsome Therapeutics from $108.00 to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $123.85.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 7,910 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the transaction, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $429,734.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Axsome Therapeutics news, Director Mark Coleman sold 5,249 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the transaction, the director now directly owns 19,848 shares in the company, valued at $1,492,768.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Mark L. Jacobson sold 7,910 shares of Axsome Therapeutics stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total value of $587,792.10. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $429,734.73. The disclosure for this sale can be found here. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.